Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Primary Cardiac Lymphoma: Italian Multicenter Experience

NCT05819528 · tracked via the Priya Life Science Italy tracker
Phase
Observational
Started
2024-10-02
Last updated
2026-08-24

Condition(s) studied

Primary Cardiac Lymphoma

Study summary

The rationale of this study is to provide an overview on PCL (Primary Cardiac Lymphoma) in Italy, trying to shed light on unknown aspects of the disease and on unanswered questions about its management that could be helpful in clinical practice.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of PCL (any histotype) defined as an extranodal lymphoma involving only the heart with possible involvement of the pericardium. * Age ≥18 years. * Diagnosis histologically confirmed. Cytofluorimetry analysis of pericardial fluid showing phenotypic features consistent with a primary cardiac lymphoma is permitted if a biopsy sample is not feasible/available for diagnosis; monoclonality is not accepted as a surrogate for diagnosis. * Date of diagnosis: from 1st January 2000 to 31st December 2020. * Only patients treated in first-line with chemoimmunotherapy regimens including an anti-CD20 monoclonal antibody are eligible for the study. * Signed written informed consent (in case of unreachable subject please see chapter 11.2) Exclusion Criteria: * Secondary cardiac involvement from lymphoma; primary mediastinal lymphoma with pericardial infiltration or other lymphomas with involvement of the pericardium/the heart by contiguity and primary effusion lymphoma are not included in this study. * Patients treated with chemotherapy regimens that did not include an anti-CD20 monoclonal antibody as first-line therapy. * Refuse to sign a written informed consent

Primary outcome measure(s)

  • Overall survival (OS) — The endpoint will be evaluated within 2 months from the end of data collection. The end of data collection is scheduled within the Q4 (fourth quarter) of 2023.
    Overall survival, the percentage of patients alive of the cohort (patients with cardiac lymphoma diagnosed from 01/01/2000 to 31/12/2020).

Trial sites (13)

FacilityCityRegionStatus
Azienda Ospedaliera Papa Giovanni XXIII - Ematologia Bergamo Bergamo Recruiting
ASST Spedali Civili di Brescia - Ematologia Brescia Brescia Recruiting
Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale Sant'Anna - Ematologia e fisiopatologia della coagulazione Ferrara Ferrara Recruiting
Istituto Scientifico San Raffaele - Unitа Linfomi - Dipartimento Oncoematologia Milan Milano Recruiting
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano - Ematologia Milan Milano Recruiting
ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia Milan Milano Recruiting
Ospedale S. Maria della Misericordia - Ematologia Perugia Perugia Recruiting
AOU Pisana - U.O. Ematologia Pisa Pisa Not Yet Recruiting
AO Sant'Andrea - Ematologia Roma Roma Recruiting
AOU di Sassari - Ematologia Sassari SS Recruiting
A.O.U. Città della Salute e della Scienza di Torino - Ematologia Universitaria Torino Torino Not Yet Recruiting
Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI) - SC Ematologia Trieste TS Recruiting
AOU Integrata di Verona - U.O. Ematologia Verona Verona Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05819528 on ClinicalTrials.gov ↗ ← All trials in Italy